Batoclimab (HBM9161/RVT1401) is a fully human monoclonal antibody developed by Harbour BioMed that binds to FcRn and blocks the FcRn-IgG interaction to accelerate the degradation of pathogenic autoantibodies, thereby treating various IgG-mediated autoimmune diseases; it is under clinical investigation for neuromyelitis optica spectrum disorders (NMOSD), with a Phase 1b/2a study evaluating its safety, tolerability, pharmacodynamics, and efficacy in Chinese NMOSD patients.